Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization.
about
Pathogenesis of human immunodeficiency virus infectionProteomic analysis of HIV-infected macrophagesAn envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralizationIsolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus.HIV p24 as scaffold for presenting conformational HIV Env antigens.Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable regionIn vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progressionHumoral immune responses in human HIV-1 infection clearance of initial burst of virus replication and protection against disease progression.Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. The Italian-Ugandan Cooperation AIDS Program.Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency virusesCharacterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosisHIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions.HIV pathogenesis: knowledge gained after two decades of research.The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequencesExploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.Dilute passage promotes expression of genetic and phenotypic variants of human immunodeficiency virus type 1 in cell culture.V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibodyViral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation.Biological and molecular variability of human immunodeficiency virus type 2 isolates from The GambiaThe viral envelope gene is involved in macrophage tropism of a human immunodeficiency virus type 1 strain isolated from brain tissue.Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophagesSerum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals.Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.Pathogenesis of human immunodeficiency virus infection.Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture.HIV-1 infection suppresses expression of host cell cycle-associated gene PDS5A.Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques.V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability.Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.
P2860
Q24634681-31057192-3CBC-470A-90D1-907F9BDA2A09Q33770687-7517691A-71B7-46C8-9261-D1B92B8D679BQ33784679-5095D0E3-400C-40C5-AD8D-C1A9573EE9BDQ33812812-A2D654BD-54FA-4D06-84F1-F676594B591AQ33946158-79A522BD-993B-4478-ADCF-76EF53239959Q34317545-BDAA090D-BE14-47D5-944D-CD374405455BQ34389522-C1FA655D-8341-47C5-92D5-952C52CB8488Q34471760-BED284CA-5E46-4F58-B58E-F2EC6307AE3AQ34974016-08BDD9B5-7390-46AE-A660-BA6D8249CF0BQ35224610-20727CB7-E9AC-4AAD-99B9-E054BFAA5DE4Q35315868-900548F9-47C5-4D54-B9F8-0E88EC14C6B3Q35852493-B46ECA41-5567-44F5-B0D5-BFB765ED4E49Q35853750-0F0853C8-69C2-40AA-83DB-5BF88089E7E1Q35868205-9CB789C7-8865-48B5-8CA5-CB691BBC84D7Q35914362-01826729-2AC5-4F87-A377-4FD68143B57EQ36231815-1A31CC12-A178-4819-A3EF-B87B21FE3F2BQ36249933-87D30CB6-15E9-45CD-8280-E51119C601C5Q36467649-051A31A4-12BF-41B9-B6F4-F52C764FB6E7Q36558253-CF22A18E-8875-4F28-811C-C33FC235750EQ36637273-9B077607-6D3E-4767-943D-626B3CD22F44Q36638240-BAFCF99A-93D8-4DAB-A2FE-1AA2A1FF7988Q36646318-6A3431D2-B258-477C-8AA8-12311B45FF24Q36711168-9FC38E8D-0E67-456C-8927-F7E325002624Q36782627-3E9C0570-076D-43F3-AE21-A0168590AA18Q36783052-E5AEDA9A-CE40-40BB-9317-E1741C6802FEQ36784415-016081A3-BB55-4606-B55F-9DD2AC40BDE6Q36796232-766373B4-12F3-40A0-A5EC-C3EB704C6575Q36797335-D90B42F0-6C84-4C3E-AAB1-91499C9AB73DQ36803017-C6E6F38E-A8C8-436A-B07D-418EC0A21C50Q36881981-E575CCB0-1649-417E-94F4-C68208F4E532Q37033294-FDD4D17A-13B5-4E77-A46E-2235A968D7F1Q38295676-DC82A3F5-0D51-4790-8E43-AEA28EECA727Q39439722-25CB28DE-A869-4139-AF3C-E3731A0BC430Q39484912-296DD586-232A-4E77-BD3F-CB0F1CF86F54Q39485924-690EF98C-8CBD-439A-AE17-8C3C15C08A5FQ39592261-04126059-97A7-4583-9FDF-CD868B245AF8Q39594428-7BD7DFC3-C00A-429A-B5B4-EBE85A1ADFACQ39604142-714BE892-7617-4F76-8D58-6669FD91A815Q40047131-DC83025A-C8FD-47D7-A7FD-C5C5C5AAF6EDQ40059024-E4C36F5A-05E8-4CF4-9DB1-C8FCBB2ED0CD
P2860
Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization.
description
1988 nî lūn-bûn
@nan
1988 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Identification of human immuno ...... ivity to serum neutralization.
@ast
Identification of human immuno ...... ivity to serum neutralization.
@en
Identification of human immuno ...... ivity to serum neutralization.
@nl
type
label
Identification of human immuno ...... ivity to serum neutralization.
@ast
Identification of human immuno ...... ivity to serum neutralization.
@en
Identification of human immuno ...... ivity to serum neutralization.
@nl
prefLabel
Identification of human immuno ...... ivity to serum neutralization.
@ast
Identification of human immuno ...... ivity to serum neutralization.
@en
Identification of human immuno ...... ivity to serum neutralization.
@nl
P2093
P2860
P356
P1476
Identification of human immuno ...... ivity to serum neutralization.
@en
P2093
P2860
P304
P356
10.1073/PNAS.85.8.2815
P407
P577
1988-04-01T00:00:00Z